The current markers of cancer stem cell in oral cancers.

Adenoid cystic carcinoma Cancer stem cells Mucoepidermoid carcinoma Oral cavity Oral squamous cell carcinoma Salivary gland cancers Stemness markers

Journal

Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521

Informations de publication

Date de publication:
15 May 2020
Historique:
received: 06 01 2020
revised: 19 02 2020
accepted: 01 03 2020
pubmed: 7 3 2020
medline: 28 5 2020
entrez: 6 3 2020
Statut: ppublish

Résumé

Head and neck cancer (HNC) constitute 5% of all reported cancers. Among all, the oral cavity cancer is the most frequent type of HNC which accounts for over half of HNC cases. Mouth cancer ranks the sixth leading cause of cancer-related mortality. Generally, conventional chemotherapy has shown success at decreasing relapse and metastasis rates and improves the overall prognosis. Recently, target therapy and targeted drug delivery systems have been introduced as promising treatments. The elimination of efficiency of current therapeutic strategies due to the spared cancer stem cells that cause chemotherapy resistance, relapse and metastasis. Inefficiency methodologies in the elimination of all cancer cells in the body are a major problem that remained to be resolved before to confront the new cancer therapies. Many studies imply to cancer stem cell markers as important agents for targeted anti-cancer as well as improving chemotherapy efficiencies. The potentials of targeted cancer therapy led us to search for novel markers in the mouth cancer stem cells especially in rare cancers. The aimed of this research was, first a comprehensive critical review of the previous studies on the markers of cancer stem cells in oral cancers including oral squamous cell carcinoma, salivary gland cancers, and to highlight the most common cancer stem cell markers which have potential to be exploited as indicators for the preneoplastic lesion malignancy, oral cancer progression, and/or treatment prognosis.

Identifiants

pubmed: 32135187
pii: S0024-3205(20)30231-9
doi: 10.1016/j.lfs.2020.117483
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

117483

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Auteurs

Elahe Tahmasebi (E)

Research Center for Prevention of Oral and Dental Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran.

Milad Alikhani (M)

Shahrekord University of Medical Sciences, Shahrekord, Iran.

Alireza Yazdanian (A)

Department of Veterinary, Science and Research Branch, Islamic Azad University, Tehran, Iran.

Mohsen Yazdanian (M)

Research Center for Prevention of Oral and Dental Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: drmyazdanian@yahoo.com.

Hamid Tebyanian (H)

Research Center for Prevention of Oral and Dental Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. Electronic address: tebyan.hamid@yahoo.com.

Alexander Seifalian (A)

Nanotechnology and Regenerative Medicine Commercialization Centre (Ltd), London Bioscience Innovation Centre, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH